Shanghai's SARI Pays $359M for Italian Cancer Biopharma NMS
The parts expect the closing in the first quarter 2018. Source: BioSpace
The parts expect the closing in the first quarter 2018. Source: BioSpace
The company's sales department will take the brunt of the layoffs, losing 235 jobs. Source: BioSpace
Celgene announced back in October that it was discontinuing its GED-0301 program for Crohn's disease and now that decision is costing the company $411M. Source: BioSpace
The J.P. Morgan Healthcare Conference is held every year in early January, and this year it will be Jan. 8-11 in San Francisco, as usual. Source: BioSpace
Thanks to the Republican tax legislation, pharmaceutical stocks are set to continue their heady northward trajectory in 2018. Source: BioSpace
The drug showed a significant, clinically meaningful and fast-acting improvement in depression symptoms compared to an intranasal placebo. Source: BioSpace
The drugmaker intends to expand development of therapeutic antibodies at the lab. Source: BioSpace
Evan Greebel was found guilty by a federal jury in Brooklyn of charges he conspired to commit wire fraud and securities fraud. Source: BioSpace
From 1997 through 2013, there was an average of 27 novel drugs approved in the U.S. per year. Source: BioSpace
Celgene has been unloading some of its shares in two of its investments, CRISPR Therapeutics and Atara Biotherapeutics. Source: BioSpace